Stockreport

Akcea and Ambry Genetics to Launch hATTR Compass, a Genetic Testing Program for People with Suspected Hereditary ATTR Amyloidosis

AKCEA THERAPEUTICS  (AKCA) 
Last akcea therapeutics earnings: 2/25 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.akceatx.com/media-investors/press-releases
PDF CAMBRIDGE, Mass., June 12, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ambry Genetics Corporation [Read more]